Hirohito Yamazaki

ORCID: 0000-0003-3018-2098
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hematopoietic Stem Cell Transplantation
  • Acute Myeloid Leukemia Research
  • Immune Cell Function and Interaction
  • T-cell and B-cell Immunology
  • Polyomavirus and related diseases
  • Mesenchymal stem cell research
  • Blood groups and transfusion
  • Complement system in diseases
  • Transplantation: Methods and Outcomes
  • Blood disorders and treatments
  • Cytomegalovirus and herpesvirus research
  • Immunodeficiency and Autoimmune Disorders
  • Hematological disorders and diagnostics
  • Platelet Disorders and Treatments
  • Chronic Myeloid Leukemia Treatments
  • Eosinophilic Disorders and Syndromes
  • Neutropenia and Cancer Infections
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Erythrocyte Function and Pathophysiology
  • Prenatal Screening and Diagnostics
  • Hemoglobinopathies and Related Disorders
  • Immunotherapy and Immune Responses
  • Viral-associated cancers and disorders
  • Virus-based gene therapy research

Kanazawa University
2015-2025

Kanazawa University Hospital
2015-2024

Kanazawa Medical University Hospital
2024

Nagaoka University of Technology
2024

Kanazawa Medical University
2011

Tokyo Women's Medical University
2005

Showa University
2005

Showa University Fujigaoka Hospital
2005

Third Way
2001

Toyama City Hospital
2001

IntroductionWe previously reported an interim analysis of the DADI (dasatinib discontinuation) trial. The results showed that 48% patients with chronic myeloid leukemia in phase who maintained a deep molecular response (DMR) for ≥ 1 year could discontinue second- or subsequent-line dasatinib treatment safely at median follow-up 20 months. However, from longer periods would be much more useful clinical perspective.Patients and MethodsThe trial was prospective, multicenter conducted Japan....

10.1016/j.clml.2018.03.004 article EN cc-by-nc-nd Clinical Lymphoma Myeloma & Leukemia 2018-03-18

Peripheral blood from 489 recently diagnosed patients with aplastic anaemia (AA) and 316 refractory (RA) of myelodysplastic syndrome was evaluated to characterize CD55(-)CD59(-) [paroxysmal nocturnal haemoglobinuria (PNH)]-type cells associated bone marrow (BM) failure. PNH-type were detected in 57% 20% AA RA, respectively. The percentages granulocytes ranged 0.003% 94.2% the distribution log-normal a median 0.178%. Serial analyses 75 over 5 years revealed that percentage constantly...

10.1111/j.1365-2141.2009.07822.x article EN British Journal of Haematology 2009-07-28

K. Ishiyama, T. Katagiri, Ohata, Hosokawa, Y. Kondo, H. Yamazaki, A. Takami, S. Nakao. Safety of pre‐engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation. Transpl Infect Dis 2011. All rights reserved Abstract: Human herpesvirus‐6 (HHV‐6) is a major cause limbic encephalitis with dismal prognosis hematopoietic transplantation (SCT). Because our previous trial preemptive therapy sodium (phosphonoformic acid; PFA) failed to prevent HHV‐6 encephalitis, we...

10.1111/j.1399-3062.2011.00662.x article EN Transplant Infectious Disease 2011-07-28

A prospective multicenter Phase II study was performed to examine the efficacy and safety of imatinib therapy in newly diagnosed Japanese patients with chronic-phase CML. Patients were scheduled receive 400 mg daily. Plasma concentrations measured by liquid chromatography-tandem mass spectrometry. In 481 evaluable patients, estimated 7-year overall survival (OS) event-free (EFS) at a median follow-up 65 months 93% 87%, respectively. Because dosage reduced many due mainly adverse events,...

10.1111/j.1349-7006.2012.02253.x article EN other-oa Cancer Science 2012-02-25

Allogeneic bone marrow transplantation is an essential therapy for acquired aplastic anemia and prognosis has recently improved. However, engraftment failure graft-versus-host disease are potential fatal complications. Various risk factors poor have been identified, such as patient age human-leukocyte antigen disparity, but the relationship between donor still unknown. Therefore, we performed a cohort study to compare of unrelated from younger older donors using registry database in Japan....

10.3324/haematol.2015.139469 article EN cc-by-nc Haematologica 2016-02-08

Abstract: To clarify the pathologic significance of granulocytes exhibiting paroxysmal nocturnal haemoglobinuria (PNH) phenotype in patients with aplastic anaemia (AA), we examined peripheral blood from 100 AA for presence deficient glycosylphosphatidylinositol (GPI)‐anchored proteins using a sensitive flow cytometric assay. A significant increase frequency CD55 − CD59 CD11b + (>0.003%) compared to normal individuals was observed 31 35 (88.6%) untreated at diagnosis. The proportions...

10.1034/j.1600-0609.2001.00376.x article EN European Journal Of Haematology 2001-03-01

Some patients with myelodysplastic syndrome (MDS) show a marked increase in the percentage of immature platelet fraction (IPF%) despite absence severe thrombocytopenia. To determine significance such an unbalanced IPF%, we investigated IPF% and other laboratory findings 51 recently diagnosed MDS.Subjects consisted 80 healthy males, 90 females, MDS 20 idiopathic thrombocytopenic purpura (ITP). The IPF were determined using Sysmex XE-2100 system loaded Master software (XE Master, Sysmex)....

10.1111/j.1600-0609.2008.01156.x article EN European Journal Of Haematology 2008-09-17

Earlier reports suggested that umbilical cord blood transplantation (UCBT) for aplastic anemia (AA) was feasible in alternative transplantation. To identify differences outcomes of UCBT and HLA-matched or mismatched unrelated bone marrow (UBMT) adults with AA, we analyzed registry data the Japan Society Hematopoietic Cell Transplantation compared results (n = 69) to 8/8-matched 101), 7/8-matched 65), 6/8-matched 37) UBMT. The period from 2002 2012, patients 16 years older AA were eligible....

10.1016/j.bbmt.2016.07.002 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2016-07-09

Mixed chimerism (MC) and/or secondary graft failure (SGF) with recipient- or donor-type is a major obstacle in allogeneic transplantation for aplastic anemia (AA). From registry database Japan, patients AA age >15 years who underwent first bone marrow peripheral blood stem cell between 2000 and 2014 achieved engraftment were included this study. MC that did not require either granulocyte-colony stimulating factor (G-CSF) transfusion support (group 1), (not SGF) required G-CSF 2), SGF...

10.1016/j.bbmt.2019.10.004 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2019-10-13

Abstract Although there are anecdotal reports of the efficacy danazol in treatment aplastic anemia (AA), has been no systematic study to clarify its and toxicity. Therefore, we assessed for patients with AA refractory immunosuppressive therapy (IST) those who relapsed after IST, a prospective clinical trial. Sixteen (12 males four females; six severe cases 10 moderate cases) were treated 300 mg daily 12 weeks. All completed period without occurrence Three female achieved partial remission,...

10.1002/ajh.21118 article EN American Journal of Hematology 2007-12-27
Coming Soon ...